Medicaid Drug Rebate Program: Inadequate Oversight Raises Concerns about Rebates Paid to States
GAO-05-850T
Published: Jun 22, 2005. Publicly Released: Jun 22, 2005.
Skip to Highlights
Highlights
To help control Medicaid spending on drugs, states receive rebates from pharmaceutical manufacturers through the Medicaid drug rebate program. Rebates are based on two prices--best price and average manufacturer price (AMP)--reported by manufacturers. GAO was asked to discuss issues relating to the rebate program and in February 2005 issued a report, Medicaid Drug Rebate Program: Inadequate Oversight Raises Concerns about Rebates Paid to States (GAO-05-102). For that report, GAO reviewed program guidance and OIG reports and conducted an analysis of rebates for brand name drugs. This testimony is based on the February 2005 report.
Full Report
Office of Public Affairs
Topics
Data integrityDrugsHealth care cost controlHealth insuranceManufacturing industryMedicaidPharmaceutical industryPrices and pricingRebatesPharmacy benefit managers